From a clinical perspective, these findings suggest that AURKA-targeted strategies may require etiological stratification, with PLK1-centered approaches potentially being more relevant in Cr-HCC, whereas therapeutic strategies focusing on the p53/BRCA1 axis may be more applicable in HBV-associated disease. This evidence concerns the gene AURKA and hepatocellular carcinoma.